Medical Cannabis Evidence-Based Care: Endocannabinoid System Clinical Research and Cannabinoid Clinical Trials
Clinical Takeaway
People experiencing a first episode of psychosis have measurable rates of criminal legal involvement both before and after entering treatment, with specific individual factors predicting who is at greatest risk. Early identification of these risk factors during the initial treatment period may help clinicians prioritize coordinated care and social support to reduce legal system contact. This research underscores that criminal legal involvement in first-episode psychosis is a clinical and social concern that warrants proactive screening, not just psychiatric stabilization.
#16 Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.
Citation: Scanlon Faith et al.. Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.. The Journal of clinical psychiatry. 2026. PMID: 41920015.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Abstract: Objective: Because limited research has evaluated criminal legal involvement (CLI) during a first episode of psychosis (FEP), we explored rates, correlates, and predictors of CLI among people with FEP. Methods: We conducted a secondary analysis on the Recovery After an Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study, a cluster randomized controlled trial conducted from 2010 to 2012 with people experiencing FEP in the US. We explored rates of recent CLI prior to baseline and over the 2-year follow-up and evaluated predictors of CLI at baseline and over the follow-up period (N = 381). Results: At baseline, 11% of the sample reported CLI within the past month, which was significantly associated with lower education, longer duration of untreated psychosis, lifetime alcohol or any drug use disorder (other than cannabis), and more severe excitement factor symptoms on the Positive and Negative Syndrome Scale (PANSS). Over the 2-year follow-up, 13.6% of the sample reported CLI which, controlling for baseline CLI, was predicted by longer duration of untreated psychosis, schizophrenia diagnosis, lifetime alcohol or any other drug use disorder, alcohol or cannabis use in the 30 days prior to baseline, and more severe positive and excitement symptoms on the PANSS at baseline. Those with CLI at baseline were nearly 3 times more likely to have subsequent CLI over the follow-up. Baseline CLI was associated with dropping out of treatment due to incarceration. Conclusion: The findings suggest that CLI in people with FEP could be reduced by earlier detection and more effective treatment of psychotic symptoms, substance use, and criminogenic risk factors. Trial Registration: Data used in this secondary analysis are from ClinicalTrials.gov identifier: NCT01321177.
What This Study Teaches Us
In people experiencing their first episode of psychosis, about 1 in 9 report criminal legal involvement over a 2-year period. This involvement is strongly predicted by longer delays before treatment starts, substance use disorders, and current alcohol or cannabis use in the month before baseline, independent of psychosis severity alone.
Why This Matters Clinically
Clinicians managing first-episode psychosis need to recognize that criminal legal involvement is a real risk that tracks with modifiable factors like treatment delay and substance use. Early intervention on these fronts may prevent both the human and systemic harms of incarceration, which itself disrupts treatment continuity.
Study Snapshot
| Study Design | Secondary analysis of a cluster randomized controlled trial (RAISE-ETP), conducted 2010-2012 |
| Population | N=381 people with first-episode psychosis in the United States; demographics not detailed in abstract |
| Intervention | Not specified; secondary analysis of existing trial data |
| Primary Outcome | Rates, correlates, and predictors of criminal legal involvement at baseline and over 2-year follow-up |
| Key Result | 13.6% reported CLI over follow-up, predicted by duration of untreated psychosis, schizophrenia diagnosis, substance use disorders, recent alcohol or cannabis use, and higher baseline positive/excitement symptoms; baseline CLI predicted 3-fold increased risk of future CLI |
Where This Paper Deserves Skepticism
This is a secondary analysis of a trial designed for a different primary purpose, so the CLI outcomes may not have been measured or captured as rigorously as a prospective study would require. The abstract does not specify how CLI was assessed (self-report? administrative records?), which matters greatly for validity. The study population and baseline demographics are not described, limiting our ability to judge generalizability to diverse clinical settings. We cannot determine from the abstract whether substance use was a confounder, mediator, or independent predictor, which changes the clinical interpretation significantly.
Dr. Caplan’s Take
This study adds useful population-level evidence that criminal legal involvement in early psychosis is not random; it clusters around treatable factors like treatment delay and active substance use. I read the cannabis finding with appropriate caution because the study does not isolate cannabis from other drugs or alcohol, and the direction of causality remains unclear. That said, the message for frontline clinicians is straightforward: aggressive early detection and treatment of psychosis, coupled with substance use screening and intervention, appears to reduce downstream legal involvement. This is a public health argument, not a pharmacology argument, but it’s worth factoring into how we triage and engage young people in their first psychotic episode.
Clinical Bottom Line
In first-episode psychosis, criminal legal involvement is predicted by delays in treatment, substance use disorders, and active substance use in the month before baseline. Clinicians should prioritize early engagement, rapid symptom treatment, and substance use assessment as practical ways to reduce this risk.
|
Have thoughts on this? Share it:
